CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2004-11-10): Anti-TNF therapy may be safe for patients with hepatitis C

Clinical

Anti-TNF therapy may be safe for patients with hepatitis C

Last Updated: 2004-11-10 15:24:42 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Patients with chronic hepatitis C (HCV) infection can apparently take anti-tumor necrosis factor (TNF) agents as treatment for rheumatoid arthritis (RA) without causing persistently elevated liver enzymes, physicians at the University of Texas-Houston Health Science Center report.

There is a concern that immune suppression resulting from anti-TNF therapy could be deleterious to the health of patients with HCV, Drs. Frank A. Parke and John D. Reveille note in their paper, published in the October 15th issue of Arthritis and Rheumatism. On the other hand, evidence suggests that HCV pathogenesis may be mediated by upregulation of TNF-alpha and other cytokines, so in theory, anti-TNF therapy may be of benefit for these patients.

For this study, the authors reviewed the charts of five patients with HCV and RA undergoing treatment with infliximab or etanercept. During an average follow-up of 41 months, patients did not develop jaundice or clinical manifestations of hepatic insufficiency, the authors write. There were no sustained elevations in aspartate aminotransferase and alanine aminotransferase levels.

HCV load varied among the patients. One patient showed a linear decrease in viral load over approximately 2 years, whereas just one displayed an exponential rise over approximately 15 months.

"I don't let a person's HCV status determine whether or not we will give them a TNF blocker, because it does not seem to be an issue," Dr. Reveille told Reuters Health.

"The same thing holds true for patients with HIV and RA, so long as their HIV is well controlled," he added. "In that setting there is no worsening of the disease and the drugs are well tolerated and efficacious."

But, Dr. Reveille indicated, "if you anticipate using these drugs for patients with HIV or HCV, you should monitor them closely for evidence of disease reactivation and for evidence that the patient is not doing badly with the disease up front, because in those situations it's a little more dangerous."

Arthritis Rheum 2004;51:800-804.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.